A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
This variant is sometimes referred to as "cooking the absinthe" or "the flaming green fairy". The origin of this burning ritual may borrow from a coffee and brandy drink that was served at Café Brûlot, in which a sugar cube soaked in brandy was set aflame. Most experienced absintheurs do not recommend the Bohemian Method and consider it a modern gimmick, as it can destroy the absinthe flavour and present a fire hazard due to the unusually high alcohol content present in absinthe.
{\displaystyle {\begin{aligned}E&=G(2+2\nu )&&=K(3-6\nu )&&={\frac {9KG}{3K+G}}\\G&={\frac {E}{2+2\nu }}&&={\frac {K(3-6\nu )}{2+2\nu }}&&={\frac {E}{3-{\frac {E}{3K}}}}\\K&={\frac {G(2+2\nu )}{3-6\nu }}&&={\frac {E}{3-6\nu }}&&={\frac {EG}{9G-3E}}\\\nu &={\frac {E}{2G}}-1&&={\frac {1}{2}}-{\frac {E}{6K}}&&={\frac {3K-2G}{2(3K+G)}}\\\end{aligned}}}
Many bird species migrate to take advantage of global differences of seasonal temperatures, therefore optimising availability of food sources and breeding habitat. These migrations vary among the different groups. Many landbirds, shorebirds, and waterbirds undertake annual long-distance migrations, usually triggered by the length of daylight as well as weather conditions. These birds are characterised by a breeding season spent in the temperate or polar regions and a non-breeding season in the tropical regions or opposite hemisphere. Before migration, birds substantially increase body fats and reserves and reduce the size of some of their organs. Migration is highly demanding energetically, particularly as birds need to cross deserts and oceans without refuelling. Landbirds have a flight range of around 2,500 km (1,600 mi) and shorebirds can fly up to 4,000 km (2,500 mi), although the bar-tailed godwit is capable of non-stop flights of up to 10,200 km (6,300 mi). Some seabirds undertake long migrations, with the longest annual migrations including those of Arctic terns, which were recorded travelling an average of 70,900 km (44,100 mi) between their Arctic breeding grounds in Greenland and Iceland and their wintering grounds in Antarctica, with one bird covering 81,600 km (50,700 mi), and sooty shearwaters, which nest in New Zealand and Chile and make annual round trips of 64,000 km (39,800 mi) to their summer feeding grounds in the North Pacific off Japan, Alaska and California. Other seabirds disperse after breeding, travelling widely but having no set migration route.
Sources: en.wikipedia.org
Vitamin D deficiency was found to be related to neurological manifestations and the presence of lymphoma among patients. Vitamin A levels were inversely associated with extraglandular manifestations of the disease. Saliva is a potential diagnostic tool for Sjögren's disease because the salivary component is changed after the onset of the disease. With the new miniaturization technology, called lab on a chip, the diagnosis can be more convenient. Concerning therapeutics, multiple monoclonal antibodies were under investigation in 2007. The most promising seemed to be the anti-CD20 rituximab and the anti-CD22 epratuzumab, while the anti-TNF-α and IFN-α seemed less effective. In 2014, the Sjögren's Foundation (previously the Sjögren's Syndrome Foundation) announced a five-year goal to halve the disease's average time to diagnosis. As of 2026, several investigational therapies were in late-stage clinical development for Sjögren's disease. In January 2026, the FDA granted ianalumab Breakthrough Therapy designation for Sjögren's disease. Other agents in phase III development include telitacicept and dazodalibep.
Certain chemicals, including hormones, can influence the composition of the ligaments. An example of this is seen in the menstrual cycle, where hormones are secreted to create changes in the uterine and pelvic floor fascia. The hormones are not site-specific, however, and chemoreceptors in other ligaments of the body can be receptive to them as well. The ligaments of the knee may be one of the areas where this happens, as a significant association between the ovulatory phase of the menstrual cycle and an increased likelihood for an anterior cruciate ligament injury has been demonstrated.
Binds to the progesterone receptor (PR) and to an unidentified membrane receptor that drives Prostaglandin E2 (PGE₂) synthesis via COX-2 induction. Induces a feed-forward loop in which PGE₂ amplifies BMP2 expression, accelerating osteogenic and chondrogenic differentiation. Causes sustained phosphorylation of PKCε, an isoform linked to suppression of the hypertrophic cartilage marker MATN1 and to formation of articular-cartilage (interzone) phenotypes. Pharmacological blockade of either PR (mifepristone) or COX-2 (indomethacin) abolishes these effects, confirming that stanozolol’s osteochondral activity requires simultaneous PR signaling and PGE₂-driven crosstalk with the BMP2 pathway. Additionally, stanozolol has been shown to exert activity via estrogen receptor alpha (ERα) in vivo. In a rat model of GnRH agonist-induced growth plate suppression, stanozolol restored chondrocyte proliferation via ERα activation, indicating selective estrogen receptor-mediated effects in growth plate cartilage.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.